Transparency Matters: Assessing Harms Reporting Compliance in Randomized Controlled Trials Underpinning the AAOS Clinical Practice Guideline for Anterior Cruciate Ligament Injuries.
Jim BrownLuke DiCiccoSamuel ShepardGriffin HughesSteven BennettJ Michael AndersonChad HansonMatt HecklerPublished in: The American journal of sports medicine (2024)
Harms were infrequently reported in RCTs cited as supporting evidence in the AAOS CPG for the management of ACL tears. One encouraging finding was the positive correlation between the year when RCTs were published and how well they adhered to reporting harms. Efforts to improve adverse event reporting are warranted, as RCTs are commonly used to make clinical decisions in orthopaedic surgery.
Keyphrases
- adverse drug
- anterior cruciate ligament
- randomized controlled trial
- minimally invasive
- dna methylation
- coronary artery bypass
- emergency department
- gene expression
- electronic health record
- clinical trial
- atrial fibrillation
- coronary artery disease
- meta analyses
- acute coronary syndrome
- percutaneous coronary intervention
- anterior cruciate ligament reconstruction